Teva’s Emrusolmin Receives U.S. FDA Fast Track Designation for Multiple System Atrophy
Wednesday, September 10, 2025
Teva Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational therapy emrusolmin (TEV-56286) for the treatment of Multiple System Atrophy (MSA).
MSA is a rare and progressive neurodegenerative disease with no available cure. It is classified as an atypical parkinsonism and is part of the group of disorders known as synucleinopathies. The condition is caused by abnormal deposits of the α-synuclein protein, mainly in glial cells, leading to severe autonomic dysfunction and movement disorders such as parkinsonian symptoms, ataxia, and speech difficulties.
Emrusolmin is designed to target pathological alpha-synuclein oligomers, aiming to address the underlying disease process. The Fast Track designation is intended to speed up the development and review of treatments for serious conditions with high unmet medical needs, supporting progress towards potential new options for people affected by MSA.
Emrusolmin is being developed through a collaboration with German biotech company MODAG GmbH and is currently in a Phase 2 clinical trial assessing its efficacy and safety. The therapy had previously received Orphan Drug designation from the FDA in 2022.
The disease affects around 40,000 people in the US, EU, and Japan, with approximately 6,000 new cases identified each year.
Life expectancy after diagnosis is usually between seven and ten years. Current treatment options are limited to symptom management, highlighting the urgent need for new therapies.
Source: tevapharm.com
